PMID- 10563607
OWN - NLM
STAT- MEDLINE
DCOM- 19991130
LR  - 20220411
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 53
IP  - 8
DP  - 1999 Nov 10
TI  - Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy 
      Cause and Treatment (INCAT) Group.
PG  - 1648-54
AB  - OBJECTIVES: To determine the prevalence and severity of ongoing fatigue and to 
      investigate the internal consistency, reliability, and validity of the Fatigue 
      Severity Scale (FSS) in patients with immune-mediated polyneuropathies. METHODS: 
      The FSS was assessed in 113 patients who either experienced Guillain-Barre 
      syndrome in the past or currently have a stable, chronic, inflammatory 
      demyelinating polyradiculoneuropathy or a polyneuropathy associated with a 
      monoclonal gammopathy of undetermined significance, and in 113 age- and 
      sex-matched healthy controls. Data on four additional scales (Medical Research 
      Council sumscore, functional grading scale [f-score], INCAT sensory sumscore, 
      medical outcome study 36-items health survey [SF-36]) were obtained in all 
      patients. SF-36 also was assessed in 59 controls. RESULTS: "Severe" fatigue (FSS 
      scores > or =95th percentile values in controls) was present in 80% of the 
      patients. Fatigue was not significantly related to general strength, sensory 
      deficits, f-score, and duration of symptoms. Severe fatigue was reported in 81% 
      to 86% of patients with normal strength or sensation. Eighty percent of the 
      patients (controls, 12%) reported their fatigue being among the three most 
      disabling symptoms. SF-36 health status scores in the patient group were 
      significantly lower than the obtained values of the controls and partially 
      related to the FSS scores. Good internal consistency, significant reliability, 
      and validity were obtained for the FSS. CONCLUSION: Fatigue is a major symptom in 
      patients with immune-mediated polyneuropathies and may persist for years after 
      apparent recovery. The Fatigue Severity Scale seems appropriate for assessing 
      fatigue in these patients because good internal consistency, reliability, and 
      validity were demonstrated.
FAU - Merkies, I S
AU  - Merkies IS
AD  - Department of Neurology, Erasmus University Medical Centre Rotterdam, The 
      Netherlands.
FAU - Schmitz, P I
AU  - Schmitz PI
FAU - Samijn, J P
AU  - Samijn JP
FAU - van der Meche, F G
AU  - van der Meche FG
FAU - van Doorn, P A
AU  - van Doorn PA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cross-Sectional Studies
MH  - Evaluation Studies as Topic
MH  - Fatigue/epidemiology/*etiology/physiopathology
MH  - Female
MH  - Guillain-Barre Syndrome/*complications
MH  - Health Surveys
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Paraproteinemias/*complications
MH  - Polyneuropathies/*complications
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*complications
MH  - Prevalence
MH  - Reference Values
MH  - Severity of Illness Index
EDAT- 1999/11/24 00:00
MHDA- 1999/11/24 00:01
CRDT- 1999/11/24 00:00
PHST- 1999/11/24 00:00 [pubmed]
PHST- 1999/11/24 00:01 [medline]
PHST- 1999/11/24 00:00 [entrez]
AID - 10.1212/wnl.53.8.1648 [doi]
PST - ppublish
SO  - Neurology. 1999 Nov 10;53(8):1648-54. doi: 10.1212/wnl.53.8.1648.